Thank you to our 801 advocates who used AAHF’s Action Center to submit comments in response to Docket Number FDA-200-N-0247, letting the Food and Drug Administration’s Transparency Task Force know that you support increased transparency at the FDA. On August 6, AAHF proudly hand-delivered 801 letters to the FDA’s Division of Docket Management. These comments will now be logged with the FDA.
AAHF has long expressed concern over the lack of transparency in FDA’s activities — in everything from its response to Citizen Petitions to the approval of a new drug or medical device that is “safe for market use.” Open government is essential to ensure accountability and is an important first step toward eliminating undue influence and conflicts of interest.
Although the FDA has told AAHF that the period for submitting comments will be extended, this has not been officially announced to the general public. We will continue to follow this process and update you as more information becomes available. Thanks again for your support.